Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1101 | Pituitary and Neuroendocrinology 3 | ECE2019

Pegvisomant: daily versus non daily administration a single centre real life study

Dassie Francesca , Rosson Marco , Parolin Matteo , Russo Lucia , Mazzocut Sara , Martini Chiara , De Carlo Eugenio , Mioni Roberto , Fallo Francesco , Vettor Roberto , Maffei Pietro

Background: Pegvisomant (PEG) is a second line medical treatment for active acromegalic patients. PEG efficacy is between 61.5 and 92% and even if it is administered daily its long half-life suggests a possible use with a non-daily regime.Aim: We aim to compare acromegalic patients on daily PEG administration (DP) with patients on non-daily PEG administration (NDP).Methods: We studied 43 acromegalic patients under PEG treatment bet...